Current Cardiovascular Risk Reports

, Volume 2, Issue 6, pp 417–419

Single and dual blockade of the renin-angiotensin system in high-risk patients without heart failure: Lessons from ONTARGET

  • Paolo Verdecchia
  • Fabio Angeli
  • Giovanni Mazzotta
  • Chiara Dembech
  • Gianpaolo Reboldi
Invited Commentary


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    The ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547–1559.CrossRefGoogle Scholar
  2. 2.
    The Heart Outcomes Prevention Evaluation study investigators: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145–153.CrossRefGoogle Scholar
  3. 3.
    Fox KM; European Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease Investigators: Efficacy of perindopril in reduction of cardiovascular events in stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003, 362:782–788.PubMedCrossRefGoogle Scholar
  4. 4.
    The PEACE Trial Investigators: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004, 351:2058–2068.CrossRefGoogle Scholar
  5. 5.
    Dagenais GR, Pogue J, Fox K, et al.: Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006, 368:581–588.PubMedCrossRefGoogle Scholar
  6. 6.
    Biollaz J, Brunner HR, Gavras I, et al.: Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 1982, 4:966–972.PubMedCrossRefGoogle Scholar
  7. 7.
    Lakhdar R, Al-Mallah MH, Lanfear DE: Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail 2008, 14:181–188.PubMedCrossRefGoogle Scholar
  8. 8.
    Pfeffer MA, McMurray JJV, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893–1906.PubMedCrossRefGoogle Scholar
  9. 9.
    Cohn JN, Tognoni G: A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667–1675.PubMedCrossRefGoogle Scholar
  10. 10.
    McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensinconverting enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767–771.PubMedCrossRefGoogle Scholar
  11. 11.
    McMurray JV: ACE inhibitors in cardiovascular disease—unbeatable? N Engl J Med 2008, 358:1616–1616.CrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  • Paolo Verdecchia
    • 1
  • Fabio Angeli
  • Giovanni Mazzotta
  • Chiara Dembech
  • Gianpaolo Reboldi
  1. 1.Clinical Research Unit-Preventive Cardiology, Department of CardiologyHospital Santa Maria della MisericordiaPerugiaItaly

Personalised recommendations